NEW BRUNSWICK, N.J., March 12 /PRNewswire/ -- Johnson & Johnson (NYSE:
JNJ) today announced that it has received separate subpoenas from the U.S.
Attorney's Office in Philadelphia, the U.S. Attorney's Office in Boston and
the U.S. Attorney's Office in San Francisco. The subpoenas relate to
investigations by those three offices previously disclosed in SEC filings
and directed, respectively, to sales and marketing of RISPERDAL by Janssen,
TOPAMAX by Ortho-McNeil and NATRECOR by Scios -- each subsidiaries of
Johnson & Johnson.
The subpoenas request information regarding Johnson & Johnson's
corporate supervision and oversight of these three subsidiaries, including
their sales and marketing of these drugs.
Johnson & Johnson will cooperate in responding to these requests.
SOURCE Johnson & Johnson
 back to top
Related links:
http://www.jnj.com/
http://www.prnewswire.com/comp/467347.html/
CONTACT:
Jeffrey J. Leebaw, +1-732-524-3350, or Bill
Price, +1-732-524-6623, both Media Contacts; Louise Mehrotra,
+1-732-524-6491, or Stan Panasewicz, +1-732-524-2524, or Lesley
Fishman, +1-732-524-3922, all Investor Contacts
|
